Alnylam Pharma (ALNY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec21

Alnylam Pharmaceuticals Receives Multiple Buy Ratings and Insider and Institutional Trading

08:50

Dec18

PeptiDream Inc. Reaches Preclinical Milestone in Peptide-siRNA Conjugate for RNAi Therapy with Aliraam Pharmaceuticals

12:01

Dec17

Alirame Pharma Invests $250 Million in RNAi Drug Production Facility Expansion

13:01

Dec16

Aliraum Pharmaceuticals' AMVUTTRA® Approved by Health Canada

14:37

Dec15

Leerink Partners Cuts AliraM Pharmaceuticals Target Price to $351

21:02

Dec14

Morgan Stanley Maintains Hold Rating on Alnylam Pharmaceuticals

15:17

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.249 B, Net Income 251.08 M, EPS 1.84

Jul31

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 773.69 M, Net Income -66.28 M, EPS -0.5073

May1

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 594.19 M, Net Income -57.48 M, EPS -0.4432

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change